New Zealand vs Serbia: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- New Zealand
- Serbia
How they compare
Serbia currently reports 136.49 deaths against 125.08 deaths in New Zealand, a difference of 11.41 deaths.
That makes Serbia's figure about 1.1 times New Zealand's.
The two have swapped places 4 times across 35 shared years of data; in 1990 it was Serbia ahead.
New Zealand ranks 122nd and Serbia ranks 120th of 157 countries.
Across the 4 decades both report, New Zealand averaged higher in 3 and Serbia in 1.
Head to head by decade
| Decade | New Zealand | Serbia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 31.03 deaths | 0 deaths | 31.03 deaths | New Zealand |
| 2000s | 73.33 deaths | 52.91 deaths | 20.42 deaths | New Zealand |
| 2010s | 115.95 deaths | 102.45 deaths | 13.51 deaths | New Zealand |
| 2020s | 130.02 deaths | 130.42 deaths | 0.4012 deaths | Serbia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, New Zealand or Serbia?
- Serbia, at 136.49 deaths against 125.08 deaths in New Zealand as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between New Zealand and Serbia?
- 11.41 deaths, with Serbia ahead.
- How many years of comparable data are there for New Zealand and Serbia?
- 35 years are reported by both, from 1990 to 2024.
- How do New Zealand and Serbia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- New Zealand ranks 122nd and Serbia ranks 120th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.